JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on March 14, 2006; DOI: 10.1124/jpet.106.102970


0022-3565/06/3173-1356-1364$20.00
JPET 317:1356-1364, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.102970v1
317/3/1356    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martinet, W.
Right arrow Articles by Kockx, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martinet, W.
Right arrow Articles by Kockx, M. M.

CARDIOVASCULAR

Macrophages but Not Smooth Muscle Cells Undergo Benzyloxycarbonyl-Val-Ala-DL-Asp(O-Methyl)-Fluoromethylketone-Induced Nonapoptotic Cell Death Depending on Receptor-Interacting Protein 1 Expression: Implications for the Stabilization of Macrophage-Rich Atherosclerotic PlaquesFormula

Wim Martinet, Guido R. Y. De Meyer, Jean-Pierre Timmermans, Arnold G. Herman, and Mark M. Kockx

Division of Pharmacology, University of Antwerp, Wilrijk, Belgium (W.M., G.R.Y.D.M., A.G.H., M.M.K.), Laboratory of Cell Biology and Histology, University of Antwerp, Belgium (J.-P.T.); and Department of Pathology, General Hospital Middelheim, Antwerp, Belgium (M.M.K.)

Several lines of evidence suggest that macrophages play a key role in atherosclerotic plaque destabilization and rupture. Therefore, selective removal of macrophages from plaques via pharmacological therapy could represent a promising approach to stabilize "vulnerable," rupture-prone lesions. Yet, how macrophages can be eliminated from plaques without influencing other cell types, including smooth muscle cells (SMCs), is unknown. In the present study, we report that benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-fluoromethylketone (z-VAD-fmk), a caspase inhibitor with broad specificity, induces nonapoptotic cell death of J774A.1 and RAW264.7 macrophages but not of SMCs. Cell death was characterized by bulk degradation of long-lived proteins, processing of microtubule-associated protein light chain 3, and cytoplasmic vacuolization, which are all markers of autophagy. However, necrosis also occurred, and the number of necrotic cells rapidly increased during z-VAD-fmk treatment. Primary mouse peritoneal macrophages were resistant to z-VAD-fmk-mediated cell death, but unlike SMCs, they underwent z-VAD-fmk-mediated necrosis after pretreatment with interferon-{gamma}. Further evidence indicated that the expression level of receptor-interacting protein 1 (RIP1) mediates the sensitivity to z-VAD-fmk. Importantly, upon z-VAD-fmk treatment, J774A.1 macrophages overexpressed and secreted several chemokines and cytokines, including tumor necrosis factor (TNF) {alpha}. The combination of z-VAD-fmk and TNF{alpha}, but not TNF{alpha} alone, induced SMCs necrosis via a mechanism that required RIP1 expression. These results suggest that z-VAD-fmk, despite its selective cell death inducing capacity, would be detrimental for the stability of atherosclerotic plaques due to enlargement of the necrotic core, stimulation of inflammatory responses, and indirect induction of SMC death.


Received for publication February 14, 2006
Accepted March 13, 2006.

Address correspondence to: Dr. Wim Martinet, Division of Pharmacology, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium. E-mail: wim.martinet{at}ua.ac.be




This article has been cited by other articles:


Home page
Circ. Res.Home page
W. Martinet and G. R.Y. De Meyer
Autophagy in Atherosclerosis: A Cell Survival and Death Phenomenon With Therapeutic Potential
Circ. Res., February 13, 2009; 104(3): 304 - 317.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Mack, A. Sickmann, D. Lembo, and W. Brune
Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein
PNAS, February 26, 2008; 105(8): 3094 - 3099.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. J.L. Van De Parre, W. Martinet, S. Verheye, M. M. Kockx, G. Van Langenhove, A. G. Herman, and G. R.Y. De Meyer
Mitochondrial uncoupling protein 2 mediates temperature heterogeneity in atherosclerotic plaques
Cardiovasc Res, January 15, 2008; 77(2): 425 - 431.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
V. Croons, W. Martinet, A. G. Herman, J.-P. Timmermans, and G. R. Y. De Meyer
Selective Clearance of Macrophages in Atherosclerotic Plaques by the Protein Synthesis Inhibitor Cycloheximide
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 986 - 993.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.